Literature DB >> 2894176

Insulin resistance after oral glucose tolerance testing in patients with major depression.

A Winokur1, G Maislin, J L Phillips, J D Amsterdam.   

Abstract

An association between affective disorders and alterations in glucose utilization has been recognized. The authors administered a 5-hour oral glucose tolerance test (GTT) to 28 depressed patients and 21 healthy volunteer control subjects and measured serum glucose as well as plasma insulin and glucagon responses. Depressed patients demonstrated significantly higher basal glucose levels, greater cumulative glucose responses after the GTT, and larger cumulative insulin responses after the GTT than control subjects. Values for cumulative glucagon did not significantly differ between groups. These findings indicate the presence of a functional state of insulin resistance during major depressive illness and suggest the presence of a more generalized biological disturbance in some depressed patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894176     DOI: 10.1176/ajp.145.3.325

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

1.  Race/ethnicity, sleep duration, and diabetes mellitus: analysis of the National Health Interview Survey.

Authors:  Ferdinand Zizi; Abhishek Pandey; Renee Murrray-Bachmann; Miriam Vincent; Samy McFarlane; Gbenga Ogedegbe; Girardin Jean-Louis
Journal:  Am J Med       Date:  2012-02       Impact factor: 4.965

2.  IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depression.

Authors:  Cicek Hocaoglu; Birgul Kural; Rezzan Aliyazıcıoglu; Orhan Deger; Sevil Cengiz
Journal:  Metab Brain Dis       Date:  2012-06-19       Impact factor: 3.584

Review 3.  Depression and osteoporosis: epidemiology and potential mediating pathways.

Authors:  B Mezuk; W W Eaton; S H Golden
Journal:  Osteoporos Int       Date:  2007-09-01       Impact factor: 4.507

4.  Examining a bidirectional association between depressive symptoms and diabetes.

Authors:  Sherita Hill Golden; Mariana Lazo; Mercedes Carnethon; Alain G Bertoni; Pamela J Schreiner; Ana V Diez Roux; Hochang Benjamin Lee; Constantine Lyketsos
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

5.  The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging.

Authors:  Christopher M Marano; Clifford I Workman; Christopher H Lyman; Elisse Kramer; Carol R Hermann; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg; Gwenn S Smith
Journal:  Psychiatry Res       Date:  2014-02-01       Impact factor: 3.222

6.  Recent advances in understanding depression in adults with diabetes.

Authors:  Patrick J Lustman; Sue M Penckofer; Ray E Clouse
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

7.  Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males.

Authors:  Yi-Chyan Chen; Wei-Win Lin; Yu-Jung Chen; Wei-Chung Mao; Yi-Jen Hung
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

8.  Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

Authors:  Enrico Domenici; David R Willé; Federica Tozzi; Inga Prokopenko; Sam Miller; Astrid McKeown; Claire Brittain; Dan Rujescu; Ina Giegling; Christoph W Turck; Florian Holsboer; Edward T Bullmore; Lefkos Middleton; Emilio Merlo-Pich; Robert C Alexander; Pierandrea Muglia
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

9.  Neurocognitive impairment and comorbid depression in patients of diabetes mellitus.

Authors:  R K Solanki; Vaibhav Dubey; Deepti Munshi
Journal:  Int J Diabetes Dev Ctries       Date:  2009-07

10.  Acute psychological stress results in the rapid development of insulin resistance.

Authors:  Li Li; Xiaohua Li; Wenjun Zhou; Joseph L Messina
Journal:  J Endocrinol       Date:  2013-04-15       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.